(redirected from NRTI)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.
See: deterrent
References in periodicals archive ?
These are two serious and undesired side-effects associated with some other NRTIs.
Recommended third-line ART regimens in the WHO 2016 guidelines [5] are: (i) darunavir/ritonavir (DRV/r) plus dolutegravir (DTG) (or raltegravir (RAL)) with or without one to two nucleoside reverse transcriptase inhibitors (NRTIs); (ii) DRV/r plus two NRTIs with or without one NNRTI; or (iii) RAL (or DTG) plus two NRTIs, depending on the preceding first- and second-line ART regimens.
The most frequent mutations in all years for NRTI were: M184V (77.
This limitation can be justified by standard criteria currently using the protocol for treatment of adult HIV positive patients, which recommends that the initiation of ART is performed with 2 NRTI + NNRTI, particularly EFZ600 + ATC.
Some studies have also shown that people treated with AZT have smaller increases in CD4 cell count compared with individuals taking alternative NRTIs.
Patients were then randomized to open-label treatment with or without an NRTI.
Any of the following 2-drug NRTI combinations are recommended for use with the NNRTI:
Hasta tani kondugu donemden itibaren enfeksiyon hastaliklari kliniginde NORTI (efavirenz 600 mg/gun) ve NRTI (tenofonir disoproksil 245 mg/gun + emtrisitabin 200 mg/gun) kombine tedavisi altinda takip edilmekte.
The proportion of births that were premature was higher in the protease-inhibitor group (23%) than in the NRTI (15%) or observational group (10%).
KIPyV WUPyV HAART 1 + - None 2 + - None 3 + - None 4 + - NRTI: FTC, TDF; PI: ATV, RTV 5 - + NNRTI: EFV; NRTI: 3TC, TDF 6 - + NNRTI: NVP; NRTI: 3TC, AZT 7 - + NRTI: 3TC, AZT; PI: ATV, RTV 8 - + NNRTI: NVP; NRTI: ABC, TDF 9 - + None 10 - + NNRTI: EFV; NRTI: 3TC, D4T 11 - + None * KIPyV, KI polyomavirus; WUPyV, WU polyomavirus; HAART, highly active antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitor; FTC, emtricitabine; TDF, tenofovir; PI, protease inhibitor; ATV, atazanavir; RTV, ritonavir; NNRTI, nonnucleoside reverse transcriptase inhibitor; EFV, Efavirenz; 3TC, lamivudine; NVP, nevirapine; AZT, azidothymidine; ABC, D4T, stavudine.
To compare treatment success (defined as the probability of not experiencing virologic failure or discontinuation of NRTI strategy by week 48) between subjects taking a new regimen of more than two active agents (defined by a cPSS > 2.
Elvucitabine (ELV; Achillion Pharmaceuticals) is an L-cytosine nucleoside analogue reverse transcriptase inhibitor (NRTI) that has potent antiviral activity againstHIV, including strains resistant to other NRTIs.